Is Erdafitinib/Bocco the last drug for patients?

Erdafitinib (Erdafitinib) is often considered an important option for targeted therapy in the treatment of advanced urothelial cancer (bladder cancer) , but whether it is the "last drug" depends on the patient's disease course and treatment history. If FGFR mutations or amplifications are detected in patients with urothelial cancer who have failed first-line chemotherapy, immunotherapy or other targeted therapies, erdafitinib can be used as a precision treatment option. Its advantage is that targeting specific genetic abnormalities can provide additional efficacy in cases of disease recurrence or drug resistance, without having to rely entirely on traditional chemotherapy.

In some clinical practices, erdafitinib may become an effective option after multiple lines of treatment, but not every patient is the "last drug." Erdafitinib can be used as second- or third-line treatment in patients who have not received other targeted or immunotherapies. During the treatment process, if drug resistance or disease progression occurs, clinicians can consider combining other targeted drugs, immunotherapy or clinical trial options based on molecular testing results and the patient's overall condition. Therefore, erdafitinib is regarded more as a key drug in the precision treatment sequence rather than as an absolute terminal treatment option.

In addition, the targeted effect of erdafitinib can improve patients' quality of life, delay disease progression, and provide a window for possible combination treatments in the future. As more clinical studies advance, erdafitinib may be moved forward in the treatment sequence to provide an earlier and more efficient intervention program for patients with FGFR mutations.

To sum up, erdafitinib is clinically a targeted drug targeting FGFR mutations. It can be used after the failure of multiple lines of treatment, but it is not the last drug for all patients. Its function is to delay disease progression, improve efficacy, and provide the possibility for subsequent treatment. It is an indispensable part of the precise treatment of urothelial cancer.

References：https://www.balversa.com/